MEN1 and MEN2 are rare inherited cancer syndromes which express a variety of endocrine and nonendocrine tumors. The improved knowledge of molecular and clinical physiopathology of MEN syndromes, together with the availability of genetic testing, have led to earlier detection and intervention, with consequent reduction of mortality and morbidity for MEN-associated tumors. Genetic testing has gained a key role in the detection of asymptomatic patients harbouring mutations responsible for these syndrome, and allows institution of early and tailored intervention with a positive impact on the course of disease. Free full text available at www.tumorionline.it
Get full access to this article
View all access options for this article.
References
1.
BrandiM.L., GagelR.F., AngeliA., BilezikianJ.P., Beck-PeccozP., BordiC., Conte-DevolxB., FalchettiA., GheriR.G., LibroiaA., LipsC.J.M., LombardiG., MannelliM., PaciniF., PonderB.A.J., RaueF., SkogseidB., TamburranoG., ThakkerR.V., ThompsonN.W., TomassettiP., TonelliF., WellsS.A., MarxS.J.: Consensus guidelines for diagnosis and therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab, 86: 5658–5671, 2001.
2.
FalchettiA., MariniF., LuziE., GiustiF., CavalliL., CavalliT., BrandiM.L.: Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. Gen Med, 11: 825–835, 2009.
SuggS.L., NortonJ.A., FrakerD.L., MetzD.C., PisegnaJ.R., FishbeynV., BenyaR.V., ShawkerT.H., DoppmanJ.L., & JensenR.T.: A prospective study of intraoperative methods to find and resect duodenal gastrinomas. Ann Surg, 218: 138–144, 1993.
5.
GibrilF., SchumannM., PaceA., JensenR.T.: Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore), 83: 43–83, 2004.
6.
FendrichV., LangerP., WaldmannJ., BartschD.K., RothmundM.: Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg, 94: 1331–1341, 2007.
7.
GibrilF., ChenY.J., SchrumpD.S., VortmeyerA., ZhuangZ., LubenskyI.A., ReynoldsJ.C., LouieA., EntsuahL.K., HuangK., AsgharianB., JensenR.T.: Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab, 88: 1066–1081, 2003.
8.
GoudetP., MuratA., Cardot-BautersC., EmyP., BaudinE., du Boullay ChoplinH., ChapuisY., KraimpsJ.L., SadoulJ.L., TabarinA., VergèsB., CarnailleB., Niccoli-SireP., CostaA., CalenderA.: Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (groupe des tumeurs endocrines). World J Surg, 33: 1197–1207, 2009.
9.
FerollaP., FalchettiA., FilossoP., TomassettiP., TamburranoG., AveniaN., DaddiG., PumaF., RibacchiR., SanteusanioF., AngelettiG., BrandiM.L.: Thymic neuroendocrine carcinoma (carcinoid) in MEN1 syndrome: the Italian series. J Clin Endocrinol Metab, 90: 2603–2609, 2005.
10.
TanabeM., AkatsukaK., UmedaS., ShomoriK., TaniuraS., OkamotoH., KamitaniH., WatanabeT.: Metastasis of carcinoid to the arch of the axis in a multiple endocrine neoplasia patient: a case report. Spine J, 8: 841–844, 2008.
11.
MillerB.S., RusinkoR.Y., FowlerL.: Synchronous thymoma and thymic carcinoid in a woman with multiple endocrine neoplasia type 1: case report and review. Endocr Pract, 14: 713–716, 2008.
12.
SachithanandanN., HarleR.A., BurgessJ.R.: Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer, 103: 509–515, 2005.
LemosM.C., ThakkerR.V.: Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat, 29: 22–32, 2008.
15.
TurnerJ.J., LeotlelaP.D., PannettA.A., ForbesS.A., BassettJ.H., HardingB., ChristieP.T., Bowen-JonesD., EllardS., HattersleyA., JacksonC.E., PopeR., QuarrellO.W., TrembathR., ThakkerR.V.: Frequent occurrence of an intron 4 mutation in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab, 87: 2688–2693, 2002.
16.
WautotV., VercheratC., LespinasseJ., ChambeB., LenoirG.M., ZhangC.X., PorchetN., CordierM., BeroudC., CalenderA.: Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat, 20: 35–47, 2002.
17.
GracaninA., DreijerinkK.M., van der LuijtR.B., LipsC.J., HöppenerJ.W.: Tissue selectivity in multiple endocrine neoplasia type 1-associated tumorigenesis. Cancer Res, 69: 6371–6374, 2009.
18.
GeerdinkE.A., Van der LuijtR.B., LipsC.J.: Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening?Eur J Endocrinol, 149: 577–582, 2003.
19.
FalchettiA., MariniF., BrandiM.L.: Multiple neoplasia type 1. In: PagonR.A., BirdT.C., DolanC.R., StephensK., editors. GeneReviews [Internet].Seattle (WA): University of Washington, Seattle; 1993–2005 [updated 2010 Mar 2].
20.
MachensA., SchaafL., KargesW., Frank-RaueK., BartschD.K., RothmundM., SchneyerU., GoretzkiP., RaueF., DralleH.: Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf), 67: 613–622, 2007.
21.
LairmoreT.C., PiersallL.D., De BenedettiM.K., DilleyW.G., MutchM.G., WhelanA.J., ZehnbauerB.: Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg, 239: 637–645, 2004.
22.
EngC., ClaytonD., SchuffeneckerI., LenoirG., CoteG., GagelR.F., van AmstelH.K., LipsC.J., NishishoI., TakaiS.I., MarshD.J., RobinsonB.G., Frank-RaueK., RaueF., XueF., NollW.W., RomeiC., PaciniF., FinkM., NiederleB., ZedeniusJ., NordenskjoldM., KomminothP., HendyG.N., MulliganL.M.: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA, 276: 1575–1579, 1996.
23.
ZbukK.M., EngC.: Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer, 7: 35–45, 2007.
24.
Frank-RaueK., RondotS., Raue Friedhelm: Molecular genetics and phenomics of RET mutations: impact on prognosis. Mol & Cell Endocrinol, 322: 2–7, 2010.
25.
American Thyroid Association Guidelines Task Force, KloosR.T., EngC., EvansD.B., FrancisG.L., GagelR.F., GharibH., MoleyJ.F., PaciniF., RingelM.D., SchlumbergerM., WellsS.A.Jr..: Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19: 565–612, 2009.
